Ivan Jewett

Ivan Jewett is a seasoned medicinal chemist currently serving as the Director of Medicinal Chemistry at Kestrel Therapeutics since September 2024. With prior experience as Director of Medicinal Chemistry at Civetta Therapeutics, Ivan contributed to strategic initiatives achieving significant efficiency improvements. As Principal Research Investigator at Black Diamond Therapeutics, Ivan played a crucial role in developing a novel BRAF inhibitor, resulting in patents and advancement to clinical trials. Ivan's past positions include leadership roles in various organizations, with a strong research foundation established through post-doctoral work at prestigious institutions and extensive contributions in early-stage drug development, structural design, and optimization. Educational credentials include a PhD in Chemistry from The University of Texas at Austin, complemented by Bachelor's degrees in Chemistry and Philosophy from the University of Vermont.